These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34971693)

  • 1. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats.
    Hernández-Lozano I; Mairinger S; Filip T; Sauberer M; Wanek T; Stanek J; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Feb; 342():44-52. PubMed ID: 34971693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of P-glycoprotein on pulmonary disposition of the model substrate [
    Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O
    Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
    Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
    J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
    Kannan P; Brimacombe KR; Kreisl WC; Liow JS; Zoghbi SS; Telu S; Zhang Y; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2593-8. PubMed ID: 21262843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance and Sensitivity of [
    Hernández-Lozano I; Leterrier S; Mairinger S; Stanek J; Zacher AS; Breyer L; Hacker M; Zeitlinger M; Pahnke J; Tournier N; Wanek T; Langer O
    Mol Pharm; 2024 Feb; 21(2):932-943. PubMed ID: 38225758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
    Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
    Farwell MD; Chong DJ; Iida Y; Bae SA; Easwaramoorthy B; Ichise M
    Ann Nucl Med; 2013 Aug; 27(7):618-24. PubMed ID: 23572210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
    Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
    Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
    Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
    J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.
    Seneca N; Zoghbi SS; Liow JS; Kreisl W; Herscovitch P; Jenko K; Gladding RL; Taku A; Pike VW; Innis RB
    J Nucl Med; 2009 May; 50(5):807-13. PubMed ID: 19372478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
    Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
    Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
    Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
    J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.